Abstract
Background: Prostate adenocarcinoma is commonly treated with radiation and chemotherapy, but resistance and toxicity limit their success, highlighting the need for novel radiosensitizers. We investigated the effects of 7-Geranyloxycoumarin, alone and in combination with radiation, on the expression of β-catenin (CTNNB1), c-MYC, and Gankyrin (PSMD10) in prostate adenocarcinoma cells. Methods: Interactome mapping and enrichment analysis were performed using STRING. To validate their expression in prostate adenocarcinoma samples, the GEPIA2 database was used. For in vitro analysis, human prostate carcinoma PC-3 cells were pretreated with 40 µM 7-Geranyloxycoumarin and exposed to 4 Gy radiation. After 72 h, real-time PCR was performed to assess gene expression. Results: In silico analysis confirmed the interaction between CTNNB1, MYC, and PSMD10, and revealed their overexpression in prostate adenocarcinoma samples. In PC-3 cells, 7-Geranyloxycoumarin treatment significantly decreased c-MYC expression (p < 0.0001). Radiation alone and DMSO-treated irradiated cells also showed a significant reduction in c-MYC expression (p < 0.001). Conversely, combined treatment significantly increased CTNNB1 expression (p < 0.01) and decreased PSMD10 expression. Conclusion: Our study demonstrated elevated expression of CTNNB1 and decrease of c-MYC, and PSMD10 in prostate adenocarcinoma, and highlighted that 7-Geranyloxycoumarin, alone or in combination with radiation, markedly modulates their expression in PC-3 cells.